To identify a genotypic score for resistance to saquinavir boosted with ritonavir (SQV/r; 1,000/100 mg twice daily)-based regimens in protease inhibitor (PI)-experienced patients.
Methods
One-hundred and fifty-one PI-experienced patients receiving a SQV/r-containing regimen were enrolled retrospectively. The virological response (VR) was defined as the decrease in HIV RNA at months 3–5. The effect of each mutation in the protease gene on the VR to SQV/r regimen was assessed using non-parametric univariate analyses and then a step-by-step analysis was carried out using a Jonckheere-Tepstra (JT) non-parametric test to retain the group of mutations most strongly associated with VR.
Results
Among the 138 patients with detectable plasma SQV, the median VR was -1.48 [range: -4 to +1.2] log10 copies/ml. Changes at 12 codons were associated with a reduced VR to SQV/r: codons 10, 15, 20, 24, 46, 54, 62, 71, 73, 82, 84 and 90. The JT procedure led to selection of the following genotypic score, 10+15+20+ 24+62+73+82+84+90, as providing the strongest association with VR. In the 35 patients with none of the mutations in this score, the median decrease in HIV RNA was -2.24 log10 copies/ml and it was -1.88 (n=29), -1.43 (n=24), -0.52 (n=30), -0.18 (n=9), -0.11 (n=6) and -0.30 (n=5) log10 copies/ml in those with 1, 2, 3, 4, 5 and 6 mutations, respectively.
Conclusion
With this resistance score to SQV/r, the isolates were classified as having no evidence of resistance (0–2), possible resistance (3) or resistance (≥4) by grouping the number of mutations in samples for which the viral load reduction was similar.
References
1.
CameronD.W., JapourA.J., XuY.Ritonavir and saquinavir combination therapy for the treatment of HIV infection.AIDS1999; 13: 213–224.
2.
FatkenheuerG., HoetelmansR.M., HunnN.Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients.AIDS1999; 13: 1485–1489.
3.
HsuA., GrannemanG.R., CaoG.Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.Clin Pharmacol Ther1998; 63: 453–464.
4.
PloskerG.L., ScottL.J.Saquinavir: a review of its use in boosted regimens for treating HIV infection.Drugs2003; 63: 1299–1324.
5.
JacobsenH., HanggiM., OttM.In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.J Infect Dis1996; 173: 1379–1387.
6.
IvesK.J., JacobsenH., GalpinS.A.Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.J Antimicrob Chemother1997; 39: 771–779.
7.
JacobsenH., YasargilK., WinslowD.L.Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.Virology1995; 206: 527–534.
8.
EberleJ., BechowskyB., RoseD.Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.AIDS Res Hum Retroviruses1995; 11: 671–676.
9.
ShaferR.W.Rationale and Uses of a Public HIV Drug-Resistance Database.J Infect Dis2006; 194Suppl 1: S51–S58.
10.
RaceE., GilbertS.M., SheldonJ.G.Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.AIDS1998; 12: 1465–1474.
11.
CraigC., RaceE., SheldonJ.HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.AIDS1998; 12: 1611–1618.
12.
WintersM.A., SchapiroJ.M., LawrenceJ., MeriganT.C.Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.J Virol1998; 72: 5303–5306.
13.
ZolopaA.R., ShaferR.W., WarfordA.HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.Ann Intern Med1999; 131: 813–821.
14.
MarcelinA.G., DalbanC., PeytavinG.Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Antimicrob Agents Chemother2004; 48: 4687–4692.
15.
ValerL., De MendozaC., De RequenaD.G.Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.AIDS2002; 16: 1964–1966.
16.
AutarR.S., AnanworanichJ., ApateerapongW.Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.J Antimicrob Chemother2004; 54: 785–790.
17.
VoraS., MarcelinA.G., GunthardH.F.Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.AIDS2006; 20: 35–40.
18.
MarcelinA.G., FlandreP., PavieJ.Clinically relevant genotype interpretation of resistance to didanosine.Antimicrob Agents Chemother2005; 49: 1739–1744.
19.
FlandreP., MarcelinA.G., PavieJ.Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.Antivir Ther2005; 10: 479–487.
20.
JonckheereA.R.A distribution-free k-sample test against ordered alternatives.Biometrika1954; 41: 133–145.
21.
SauerbreiW., SchumacherM.A bootstrap resampling procedure for model building: application to the Cox regression model.Stat Med1992; 11: 2093–2109.
22.
Brun-VezinetF., DescampsD., RuffaultA.Clinically relevant interpretation of genotype for resistance to abacavir.AIDS2003; 17: 1795–802.
23.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the drug resistance mutations in HIV-1: Fall 2005.Top HIV Med2005; 13: 125–131.
24.
KempfD.J., IsaacsonJ.D., KingM.S.Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.Antivir Ther2002; 7: 165–174.
25.
VeldkampA.I., van HeeswijkR.P., MulderJ.W.Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.J Acquir Immune Defic Syndr2001; 27: 344–349.
26.
WuT.D., SchifferC.A., GonzalesM.J.Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.J Virol2003; 77: 4836–4847.
27.
KantorR., KatzensteinD.A., EfronB.Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.PLoS Med2005; 2: e112.
28.
LoutfyM.R., RaboudJ.M., WalmsleyS.L.Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.Antivir Ther2004; 9: 595–602.
